Flt3 ligand: A novel cytokine prevents allergic asthma in a mouse model

Devendra K. Agrawal, Michael T. Hopfenspirger, Jennifer Chavez, James E Talmadge

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

Original languageEnglish (US)
Pages (from-to)2081-2089
Number of pages9
JournalInternational Immunopharmacology
Volume1
Issue number12
DOIs
StatePublished - Oct 27 2001

Fingerprint

Asthma
Cytokines
Ovalbumin
Bronchoalveolar Lavage Fluid
Interleukin-12
T-Lymphocytes
Methacholine Chloride
Interleukin-5
Hematopoietic Stem Cells
Eosinophils
Interleukin-4
Dendritic Cells
Immunoglobulin E
Intercellular Signaling Peptides and Proteins
Therapeutics
flt3 ligand protein
Phenotype
Serum

Keywords

  • Airway hyperresponsiveness
  • Asthma
  • Eosinophilia
  • Flt-3 ligand
  • Late allergic response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Flt3 ligand : A novel cytokine prevents allergic asthma in a mouse model. / Agrawal, Devendra K.; Hopfenspirger, Michael T.; Chavez, Jennifer; Talmadge, James E.

In: International Immunopharmacology, Vol. 1, No. 12, 27.10.2001, p. 2081-2089.

Research output: Contribution to journalArticle

Agrawal, Devendra K. ; Hopfenspirger, Michael T. ; Chavez, Jennifer ; Talmadge, James E. / Flt3 ligand : A novel cytokine prevents allergic asthma in a mouse model. In: International Immunopharmacology. 2001 ; Vol. 1, No. 12. pp. 2081-2089.
@article{172cca3082794aeab4cfe8101c1a3ec7,
title = "Flt3 ligand: A novel cytokine prevents allergic asthma in a mouse model",
abstract = "Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.",
keywords = "Airway hyperresponsiveness, Asthma, Eosinophilia, Flt-3 ligand, Late allergic response",
author = "Agrawal, {Devendra K.} and Hopfenspirger, {Michael T.} and Jennifer Chavez and Talmadge, {James E}",
year = "2001",
month = "10",
day = "27",
doi = "10.1016/S1567-5769(01)00122-9",
language = "English (US)",
volume = "1",
pages = "2081--2089",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Flt3 ligand

T2 - A novel cytokine prevents allergic asthma in a mouse model

AU - Agrawal, Devendra K.

AU - Hopfenspirger, Michael T.

AU - Chavez, Jennifer

AU - Talmadge, James E

PY - 2001/10/27

Y1 - 2001/10/27

N2 - Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

AB - Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

KW - Airway hyperresponsiveness

KW - Asthma

KW - Eosinophilia

KW - Flt-3 ligand

KW - Late allergic response

UR - http://www.scopus.com/inward/record.url?scp=0034774974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034774974&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(01)00122-9

DO - 10.1016/S1567-5769(01)00122-9

M3 - Article

C2 - 11710537

AN - SCOPUS:0034774974

VL - 1

SP - 2081

EP - 2089

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 12

ER -